Global Advanced Therapy CDMO Market - Trends and Forecast Till 2035

ADVANCED THERAPY CDMO MARKET: OVERVIEW

The global advanced therapy CDMO market is estimated to grow from USD 8.75 billion in the current year to USD 36.77 billion by 2035, growing at a CAGR of 17.3% during the forecast period.

Advanced Therapy CDMO Market: Growth and Trends

Advanced therapy CDMOs provide outsourced process development, GMP manufacturing, analytical testing, and fill-finish services for gene therapies, cell therapies, and tissue-engineered products, which are significantly more complex and capital-intensive to manufacture than conventional drugs. As establishing dedicated GMP infrastructure is often uneconomical for individual rare-disease programs, outsourcing has become a preferred manufacturing strategy, particularly among small and mid-sized biotechnology companies lacking internal capabilities.

A broad clinical pipeline continues to support long-term CDMO demand. Thousands of gene, cell, and RNA therapy candidates are under development globally, with CAR-T therapies representing a major share of genetically modified cell therapy programs and oncology remaining the leading therapeutic focus. Increasing regulatory approvals, including CRISPR-based gene-editing therapies, are further expanding the pool of programs requiring specialized manufacturing, analytical, and development capabilities.

The competitive landscape is also undergoing significant consolidation and restructuring. Major transactions, manufacturing-site rationalization, and divestitures are reshaping the advanced therapy CDMO sector, while new entrants and industry spin-outs are introducing additional competition. As a result, sponsors and channel partners are navigating a more concentrated yet increasingly dynamic network of advanced therapy manufacturing providers.

Advanced Therapy CDMO Market: Growth Drivers

The expanding pipeline of gene, cell, and RNA therapies is increasing demand for specialized process development, GMP manufacturing, and analytical services. Limited patient populations and high in-house manufacturing costs are encouraging developers to outsource to CDMOs. Supportive regulatory frameworks are also increasing demand for specialized CMC and regulatory expertise. Meanwhile, M&A activity is enabling CDMOs to offer integrated development, manufacturing, fill-finish, and analytical services.

Advanced Therapy CDMO Market: Key Challenges

Specialized manufacturing capacity, analytical testing, and quality-control capabilities remain key bottlenecks in advanced therapy manufacturing. Facilities cannot be easily adapted across modalities, while specialized assays require skilled personnel and equipment. CDMO closures, divestitures, and ownership changes also create continuity risks for sponsors. Long lead times for securing capacity can further delay programs and increase competition for specialized manufacturing period.

Recent Developments Signaling Momentum

Some of the recent initiatives are listed below:

• Novo Holdings completed the acquisition of Catalent for approximately USD 16.5 billion, creating one of the largest CDMO businesses and reshaping the advanced therapy manufacturing landscape.
• GI Partners acquired Charles River Laboratories’ CDMO and Cell Solutions businesses to form Rose BioSolutions, with capabilities in plasmid DNA, viral vectors, and cell processing.
• Merck partnered with Cyto-Facto to strengthen lentiviral vector manufacturing and expand CDMO capabilities across Asia-Pacific.
• AGC Biologics entered into a manufacturing agreement for dual-AAV gene therapies targeting inherited retinal disorders, expanding its advanced viral vector capabilities.

Advanced Therapy CDMO Market Segments

The market sizing and opportunity analysis has been segmented across the following parameters:

By Product

• Gene Therapy
• Cell Therapy
• Tissue-Engineered Products
• Others (Combined ATMPs)

By Phase of Development

• Phase I
• Phase II
• Phase III
• Phase IV

By Indication

• Oncology
• Cardiology
• Central Nervous System
• Musculoskeletal
• Infectious Disease
• Dermatology
• Endocrine, Metabolic, and Genetic Disorders
• Immunology and Inflammation
• Ophthalmology
• Hematology
• Gastroenterology
• Others

By Geographical Regions

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and North Africa

Advanced Therapy CDMO Market: Key Segment Insights

Gene Therapy Leads the Market

Gene therapy accounts for the largest share of the advanced therapy CDMO market. This dominance is driven by the strong investment and a broad pipeline across oncology, neurological, cardiovascular, blood, and infectious diseases. Cell therapy CDMO services are expected to grow faster at a higher CAGR during the forecast period due to the expanding cell therapy pipelines, increasing approvals, and rising demand for specialized cell processing capabilities.

Oncology Dominates by Indication Segment

Oncology represents the largest indication segment, driven by the high disease burden and growing adoption of approved cell and gene therapies such as Kymriah and Yescarta. Cardiology is expected to grow at the fastest rate, owing to the rising cardiovascular disease prevalence, increased research activity, and expanding gene therapy programs targeting conditions such as hypertrophic cardiomyopathy.

Phase I Leads by Development Stage and Phase II Set to Expand

Phase I represents the largest share of CDMO-supported development activity, reflecting the high volume of early-stage safety and dose-finding studies in advanced therapy development. Phase II is expected to grow faster as early-stage programs progress and more therapies advance into mid-stage clinical development.

North America Dominates the Market While Asia-Pacific Register Higher CAGR

North America holds the largest regional share, supported by its strong biopharmaceutical R&D base, established outsourcing practices, and advanced regulatory environment. The U.S. accounts for most regional demand due to its large concentration of biopharmaceutical companies, biotechnology firms, academic institutions, and manufacturing infrastructure.

Asia-Pacific is expected to grow at a higher CAGR during the forecast period, supported by increasing investment in pharmaceutical and biotechnology R&D, government initiatives, and expanding CDMO capacity. Partnerships involving Thermo Fisher, Dr. Park CDMO, eXmoor Pharma, and Siam Bioscience further strengthen the region's cell and gene therapy manufacturing capabilities. Asia-Pacific is therefore becoming an important destination for manufacturing partnerships and CDMO expansion.

Example Players In The Advanced Therapy CDMO Market

• AGC Biologics
• Bio Elpida
• Catalent (a Novo Holdings company)
• Celonic
• Lonza
• Minaris Regenerative Medicine
• Rentschler Biopharma
• Samsung Biologics
• Thermo Fisher Scientific
• WuXi Advanced Therapies

ADVANCED THERAPY CDMO MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: An in-depth analysis focusing on key segments, including product, phase of development, indication, and geographical regions.
• Market Landscape: A detailed assessment of active advanced therapy CDMOs, covering headquarters location, company size, modality specialization (viral vector, cell processing, plasmid DNA, fill-finish), and scale of operation.
• Company Profiles: In-depth profiles of prominent CDMOs, covering ownership structure, facility footprint, technology platforms, and recent capacity investments or M&A activity.
• Partnerships and Collaboration Analysis: An analysis of licensing, partnership, acquisition, and divestiture activity among advanced therapy CDMOs, based on year, deal type, and most active acquirers.
• Market Impact Analysis: A detailed review of the drivers, restraints, opportunities, and challenges shaping growth, adoption, and competitive dynamics in the advanced therapy CDMO space.

KEY QUESTIONS ANSWERED IN THIS REPORT

• What is an advanced therapy CDMO?
• How big is the advanced therapy CDMO market?
• What is the projected CAGR of the advanced therapy CDMO market?
• Which region dominates the advanced therapy CDMO market, and which is growing fastest?
• Which product segment holds the largest CDMO market share?
• Who are the leading advanced therapy CDMOs?
• What opportunities exist for distributors and channel partners entering this space?

ADDITIONAL BENEFITS

• Complementary PPT Insights Pack
• Complementary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated Report if the Report is 6-12 Months Old or Older